print page

Melanocortin Receptor Obesity Program

Palatin Technologies has an exclusive global licensing and research collaboration agreement with AstraZeneca, a major international pharmaceutical and healthcare business, to discover, develop and commercialize compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.

Obesity is a global problem, with the World Health Organization estimating that over 1.5 billion adults are overweight and over 500 million are obese. Worldwide obesity has more than doubled since 1980. A number of different metabolic and hormonal pathways are being evaluated by companies around the world in efforts to develop better treatments for obesity. Scientific research has established that melanocortin receptors have a role in eating behavior and energy homeostasis, and that some melanocortin receptor agonists decrease food intake and induce weight loss in animal studies.

Palatin's melanocortin-4 receptor program for the treatment of obesity has developed compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development.  Proof of principal human studies have validated Palatin's approach to treatment of obesity.